Literature DB >> 15364965

Can we now agree to use the same definition to measure response according to CA-125?

Gordon J S Rustin.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15364965     DOI： 10.1200/JCO.2004.06.628

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

2.  The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer.

Authors:  Yan Zhang; Qian Mei; Yang Liu; Xiang Li; Malcolm V Brock; Meixia Chen; Liang Dong; Lu Shi; Yao Wang; Mingzhou Guo; Jing Nie; Weidong Han
Journal:  Oncoimmunology       Date:  2017-05-17       Impact factor: 8.110

3.  High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.

Authors:  Ming Liu; Gil Mor; Huan Cheng; Xue Xiang; Pei Hui; Thomas Rutherford; Gang Yin; David L Rimm; Jennie Holmberg; Ayesha Alvero; Dan-Arin Silasi
Journal:  Reprod Sci       Date:  2012-11-20       Impact factor: 3.060

Review 4.  Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.

Authors:  Charlotte S Marcus; G Larry Maxwell; Kathleen M Darcy; Chad A Hamilton; William P McGuire
Journal:  J Cancer       Date:  2014-01-01       Impact factor: 4.207

5.  Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods.

Authors:  E Sun Paik; Jeong Won Lee; Jeong Yeol Park; Ju Hyun Kim; Mijung Kim; Tae Joong Kim; Chel Hun Choi; Byoung Gie Kim; Duk Soo Bae; Sung Wook Seo
Journal:  J Gynecol Oncol       Date:  2019-03-11       Impact factor: 4.401

6.  Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.

Authors:  Maria Lee; Min Young Chang; Hanna Yoo; Kyung Eun Lee; Doo Byung Chay; Hanbyoul Cho; Sunghoon Kim; Young Tae Kim; Jae-Hoon Kim
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.